PRDM11

Across TCGA pan-cancer cohorts, PRDM11 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PRDM11 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uveal melanoma (UVM), where higher PRDM11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRDM11 expression acts as an unfavorable survival marker.

UVM, OV, and SARC are the cancer types where PRDM11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UVM	OS	Median	All	0.075	0.859	<.001	36	view →
OV	OS	Median	II,III,IV	0.289	0.692	.020	18	view →
SARC	OS	Median	All	0.205	0.826	<.001	6	view →
BLCA	OS	Median	III,IV	0.188	0.581	.005	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	OS	Median	II,III,IV	0.239	0.715	.035	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PRDM11–UVM (OS)

Open the UVM breakdown →